SPIA
TEVA icon

Steward Partners Investment Advisory’s Teva Pharmaceuticals TEVA Stock Holding History

Steward Partners Investment Advisory’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$88.3K Sell
2,607
-15
-0.6% -$500 ﹤0.01% 2654
2026
Q1 		$79K Buy
2,622
+1,534
+141% +$49.4K ﹤0.01% 2517
2025
Q4 		$34K Buy
1,088
+142
+15% +$3.5K ﹤0.01% 2884
2025
Q3 		$19.1K Buy
946
+19
+2% +$334 ﹤0.01% 3111
2025
Q2 		$15.5K Buy
927
+80
+9% +$1.29K ﹤0.01% 3018
2025
Q1 		$13K Buy
847
+174
+26% +$3.11K ﹤0.01% 2979
2024
Q4 		$14.8K Sell
673
-400
-37% -$7.28K ﹤0.01% 2925
2024
Q3 		$19.3K Buy
1,073
+724
+207% +$12.7K ﹤0.01% 2672
2024
Q2 		$5.67K Hold
349
– – ﹤0.01% 3001
2024
Q1 		$4.92K Hold
349
– – ﹤0.01% 3050
2023
Q4 		$3.64K Hold
349
– – ﹤0.01% 3081
2023
Q3 		$3.56K Hold
349
– – ﹤0.01% 2932
2023
Q2 		$2.63K Sell
349
-5,900
-94% -$47.8K ﹤0.01% 2975
2023
Q1 		$55.3K Buy
6,249
+64
+1% +$633 ﹤0.01% 1826
2022
Q4 		$56.4K Hold
6,185
– – ﹤0.01% 1786
2022
Q3 		$50K Sell
6,185
-860
-12% -$7.61K ﹤0.01% 1789
2022
Q2 		$53K Sell
7,045
-103
-1% -$897 ﹤0.01% 1782
2022
Q1 		$67K Hold
7,148
– – ﹤0.01% 1770
2021
Q4 		$57K Sell
7,148
-415
-5% -$3.75K ﹤0.01% 1847
2021
Q3 		$74K Hold
7,563
– – ﹤0.01% 1686
2021
Q2 		$75K Sell
7,563
-2,704
-26% -$28.6K ﹤0.01% 2643
2021
Q1 		$118K Sell
10,267
-1,354
-12% -$15.5K ﹤0.01% 1536
2020
Q4 		$112K Buy
11,621
+7,423
+177% +$71.1K ﹤0.01% 1318
2020
Q3 		$38K Sell
4,198
-16,292
-80% -$172K ﹤0.01% 1626
2020
Q2 		$253K Buy
20,490
+14,779
+259% +$167K 0.01% 805
2020
Q1 		$51K Buy
5,711
+2,609
+84% +$26.7K ﹤0.01% 1249
2019
Q4 		$30K Sell
3,102
-3,539
-53% -$31.6K ﹤0.01% 1628
2019
Q3 		$45K Buy
6,641
+3,500
+111% +$26.8K ﹤0.01% 1402
2019
Q2 		$28K Buy
+3,141
New +$37.9K ﹤0.01% 1574
2018
Q4 		– Sell
-3,517
Closed -$76K – 2018
2018
Q3 		$76K Buy
3,517
+1,456
+71% +$33.8K ﹤0.01% 1027
2018
Q2 		$50K Sell
2,061
-109
-5% -$2.22K ﹤0.01% 1100
2018
Q1 		$37K Buy
2,170
+1,320
+155% +$25.8K ﹤0.01% 1110
2017
Q4 		$16K Sell
850
-229
-21% -$3.44K ﹤0.01% 1209
2017
Q3 		$18K Buy
1,079
+9
+0.8% +$203 ﹤0.01% 968
2017
Q2 		$35K Sell
1,070
-302
-22% -$9.35K ﹤0.01% 716
2017
Q1 		$44K Buy
1,372
+178
+15% +$6.08K 0.01% 579
2016
Q4 		$43K Buy
+1,194
New +$47.7K 0.02% 341

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Steward Partners Investment Advisory's TEVA Position: Q2 2026 in Review

Steward Partners Investment Advisory reduced its Teva Pharmaceuticals (TEVA) stake by 0.57% in Q2 2026, selling an estimated $500 and leaving 2,607 shares worth $88.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2654.

Steward Partners Investment Advisory first reported a position in TEVA in Q4 2016 and has held it in 37 quarters since. The position peaked at $253K in Q2 2020. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Steward Partners Investment Advisory held 2,607 shares of Teva Pharmaceuticals worth $88.3K as of Q2 2026.
  • Steward Partners Investment Advisory sold 15 Teva Pharmaceuticals shares in Q2 2026, an estimated $500.
  • Teva Pharmaceuticals made up ﹤0.01% of Steward Partners Investment Advisory's portfolio in Q2 2026, its #2654 holding.
  • Steward Partners Investment Advisory first reported a position in Teva Pharmaceuticals in Q4 2016 and has held it in 37 quarters since.
  • Steward Partners Investment Advisory's Teva Pharmaceuticals position peaked at $253K in Q2 2020.
  • 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Steward Partners Investment Advisory's 13F filing for Q2 2026, filed 13 Aug 2026.